Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Riess

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Translational Oncology|August 1, 2021
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitorsJonathan W Riess, Shaila Rahman, Waleed Kian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
JAMA Oncology|October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical TrialNobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.
Cancer Research|September 7, 2022
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung CancerXing Yi Woo, Anuj Srivastava, Philip C Mack, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Translational Oncology|August 1, 2021
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitorsJonathan W Riess, Shaila Rahman, Waleed Kian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
JAMA Oncology|October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical TrialNobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.
Cancer Research|September 7, 2022
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung CancerXing Yi Woo, Anuj Srivastava, Philip C Mack, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 14